Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 229

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 229
---
 2025 |     |                       | 4,270,000 |   |     |          | 0.3 |     |                                        | 5.2 |     |                           | - |
| Exercisable at September 30, 2025                 |     |                       | 4,022,500 |   |     |          | 0.3 |     |                                        | 5.1 |     |                           | - |

NOTE 6: - SEGMENT REPORTING

ASC 280, “Segment Reporting,”
establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise
about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”)
in deciding how to allocate resources and in assessing performance. The Company’s business is comprised of one operating segment.
The Company’s CODM is its Chief Executive Officer (“CEO”), who reviews financial information presented on a consolidated
basis. The CODM uses consolidated net loss to measure segment profit or loss, to allocate resources and assess performance. Further,
the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level
to manage the Company’s operations and evaluate return on total assets in deciding whether to invest in the development and expansion
of the Company’s consolidated operations.

NOTE 7: - SUBSEQUENT EVENT

In 2023, the Company entered into an option
agreement with Yissum relating to a preclinical ARB formulation program. Under this agreement, the Company is entitled to receive a final
scientific report following completion of four designated preclinical studies, after which a 90-day option exercise period and 120 days
to negotiate an exclusive license. However, in November 2025, Yissum informed the Company that, in its view, the option exercise period
had already commenced and expired, based on a report Yissum considers to be the final scientific report, which Yissum claims was delivered
in September 2024. The Company disagrees with this position, noting that (i) the report delivered in 2024 did not include the components
specified in the agreement, and (ii) research activities continued thereafter with the knowledge and involvement of Yissum and University
personnel. The parties are currently engaged in discussions to resolve this disagreement, but there can be no assurance that the Company
will be successful in amicably resolving this issue.

If the Company unable to reach
an amicable